Skip to main content

A 'Valuable Service' or an Exorbitant Mark-Up?


US Congressman Elijah Cummings, a Maryland Democrat and ranking member of the US House Oversight and Government Reform Committee, has launched an investigation into the pricing policies of companies that buy cancer drugs on a secondary market and then resell them to hospitals, reports Bloomberg's Drew Armstrong and Tom Randall. Cummings says the companies are adding a "steep mark-up" to the price of the drug, while the companies claim they provide a "valuable service" to hospitals, Armstrong and Randall write. According to a survey by the Premier Healthcare Alliance, the prices these companies sell the drugs for are, on average, seven times more expensive than typical prices. Cummings, who said the companies engage in "price gouging" in a statement emailed to Bloomberg, added that found one reseller who charged a hospital 80 times the typical price for the pediatric cancer drug cytarabine. He plans to investigate where the companies are getting their supplies, and how much their profits are, Armstrong and Randall say. The resellers say the mark-ups reflect their costs and the shortage of cancer drugs currently plaguing the US. Three of the five major resellers who received a letter from Cummings say they plan to cooperate, Bloomberg adds.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.